Clinical Trials

63 enrolled

Multiple Myeloma

NCT04150289 2023-06-15

RECOMM

Completed

248 enrolled

Multiple Myeloma

NCT01238692 2023-03-24

A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)

42 enrolled

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05725200 2023-02-21

EVIDENT

Phase 2 Recruiting

40 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04326764 2023-02-16

Panobinostat Maintenance After HSCT fo High-risk AML and MDS

Phase 3 Terminated

52 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02032810 2023-01-20

Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma

17 enrolled 12 charts

Dermatologic

Melanoma, Skin Neoplasms

NCT02890069 2023-01-11

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

BreastGastrointestinalGenitourinaryThoracic

298 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT02722941 2022-11-01

Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)

30 enrolled 12 charts

Multiple Myeloma

NCT01582009 2022-08-15

Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate

Phase 1/2 Terminated

26 enrolled 11 charts

Carcinoma, Renal Cell

NCT01261247 2022-05-24

Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

LymphoidOther hematologic neoplasm

41 enrolled 8 charts

Burkitt Lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT03256045 2022-05-09

Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

9 enrolled 12 charts

Multiple Myeloma

NCT01658241 2022-05-06

VEG VCA1

30 enrolled

Multiple Myeloma

NCT01496118 2022-02-02

Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma

80 enrolled 20 charts

Multiple Myeloma

NCT00550277 2021-11-23

LBH589 Treatment for Refractory Clear Cell Renal Carcinoma

20 enrolled 7 charts

Carcinoma, Renal Cell

NCT01965353 2021-09-05

PanRVD

21 enrolled

Multiple Myeloma

NCT00425555 2021-08-20

Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma

139 enrolled 21 charts

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00490776 2021-08-18

Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)

9 enrolled 6 charts

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00742027 2021-07-28

Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma

129 enrolled 16 charts

Hodgkin Disease

NCT00449761 2021-07-15

Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase

27 enrolled 14 charts

Blast Crisis, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00445068 2021-07-14

Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma

38 enrolled 13 charts

Multiple Myeloma

NCT00667862 2021-06-21

Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer

35 enrolled 8 charts

Adenocarcinoma, Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT00936611 2021-01-28

LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia

39 enrolled 13 charts

Waldenstrom Macroglobulinemia, Recurrence

NCT01169636 2021-01-06

Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma

62 enrolled 13 charts

Hodgkin Disease

NCT00621244 2021-01-05

A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies

LymphoidOther hematologic neoplasmPlasma cell

175 enrolled 25 charts

Leukemia, Lymphoma, Multiple Myeloma

NCT00493766 2020-12-19

Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone

Phase 1 Terminated

16 enrolled

Prostatic Neoplasms

NCT00503451 2020-12-19

A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors

14 enrolled

Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms

NCT00532389 2020-12-19

Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma

62 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00532675 2020-12-19

Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.

46 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00535951 2020-12-19

Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma

Other solid neoplasmThoracic

18 enrolled

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Mesothelioma

NCT00570284 2020-12-19

A Study to Investigate the Effect of Food on Oral LBH589 Absorption in Patients With Advanced Solid Tumors

36 enrolled

Tumor-Agnostic

Neoplasms

NCT00663832 2020-12-19

A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer

44 enrolled

Neoplasms, Prostatic Neoplasms

NCT00739414 2020-12-19

Dose-escalating Study of LBH589 in Adult Patients With Advanced Solid Tumors

14 enrolled

Tumor-Agnostic

Neoplasms

NCT00788931 2020-12-19

A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer

15 enrolled

Breast

Breast Neoplasms

NCT00997399 2020-12-19

Study to Evaluate Panobinostat (DACi) Pharmacokinetics and Safety in Solid Tumors and Varying Renal Function

37 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT01007968 2020-12-19

Pharmacokinetics and Safety of Panobinostat in Patients With Advanced Solid Tumors and Various Degrees of Hepatic Function

25 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT01055483 2020-12-19

A Phase Ib, Open-label, Multi-center Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Ara-C and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia

Other hematologic neoplasm

59 enrolled

Leukemia, Myeloid, Acute

NCT01242774 2020-12-19

Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)

Other hematologic neoplasm

46 enrolled

Chromosome Aberrations, Leukemia, Myeloid, Acute

NCT01613976 2020-12-19

A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients

10 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT00823290 2020-12-14

Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC)

Phase 1 Terminated

2 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT00946647 2020-08-04

A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).

113 enrolled 21 charts